Epicatechin Gallate

Epicatechin Gallate

SCHEMBL4639313

O=C(O[C@H]1Cc2c(O)cc(O)cc2O[C@H]1c1ccc(O)c(O)c1)c1cc(O)c(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 7/20 1.00
BACE1 P56817 5/20 1.00
BCL2 P10415 4/20 1.00
PSMB5 P28074 4/20 1.00
SNCA P37840 4/20 1.00
PGD P52209 4/20 1.00
PKM P14618 3/20 1.00
MET P08581 3/20 1.00
KDM4E B2RXH2 3/20 1.00
MEN1 O00255 3/20 1.00
MAPT P10636 3/20 1.00
RECQL P46063 3/20 1.00
KMT2A Q03164 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
APP P05067 2/20 1.00
ADAMTS4 O75173 2/20 1.00
SLCO2B1 O94956 2/20 1.00
CNR1 P21554 2/20 1.00
CNR2 P34972 2/20 1.00
RAD52 P43351 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Epicatechin Gallate SCHEMBL30977096 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL39046 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
(-)-Catechingallate SCHEMBL31181360 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
(-)-Catechingallate SCHEMBL4639342 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL39047 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL13014548 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Catechin Gallate SCHEMBL145289 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL4545330 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL8426343 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA
Epicatechin Gallate SCHEMBL31297152 1.00 DYRK1A (1.00) DYRK1ABACE1BCL2PSMB5SNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030283-B2 Food packaging film with antioxidant for freshness protection INTEPLAST GROUP CORPORATION (US) 2024-07-09 US claimed
CN-119868522-A Broad-spectrum multivalent tumor cell vaccine, and preparation method and application thereof 华南理工大学 2025-04-25 CN disclosed
CN-115803074-B Medicine vaporizing inhaler 杰迪克斯帕马株式会社 2025-02-14 CN disclosed
US-12030283-B2 Food packaging film with antioxidant for freshness protection INTEPLAST GROUP CORPORATION (US) 2024-07-09 US disclosed
CN-115803074-A Medicine vaporization inhaler 杰迪克斯帕马株式会社 2023-03-14 CN disclosed
WO-2023002500-A1 SINGLE PROCESS FOR SEQUENTIAL EXTRACTION OF PRODUCTS FROM GREEN TEA LEAVES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-01-26 WO disclosed
US-20180000774-A1 METHODS OF TREATING COGNITIVE AND BEHAVIORAL IMPAIRMENT IN DOWN SYNDROME AND ALZHEIMERS DISEASE PATIENTS AVANTI BIOSCIENCES, INC (US) 2018-01-04 US disclosed
US-20160068503-A1 (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2016-03-10 US disclosed
US-9169230-B2 (−)-Epigallocatechin gallate derivatives for inhibiting proteasome THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2015-10-27 US disclosed
US-8859290-B2 Inhibitors of influenza endonuclease activity and tools for their discovery RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-10-14 US disclosed
US-8710248-B2 (−)-epigallocatechin gallate derivatives for inhibiting proteasome THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2014-04-29 US disclosed
US-20130090300-A1 INHIBITORS OF INFLUENZA ENDONUCLEASE ACTIVITY AND TOOLS FOR THEIR DISCOVERY RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2013-04-11 US disclosed
US-20130090300-A1 INHIBITORS OF INFLUENZA ENDONUCLEASE ACTIVITY AND TOOLS FOR THEIR DISCOVERY RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2013-04-11 US disclosed
US-20120232135-A1 (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2012-09-13 US disclosed
US-8193377-B2 (−)-epigallocatechin gallate derivatives for inhibiting proteasome THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2012-06-05 US disclosed
EP-1778663-A4 (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME UNIV HONG KONG POLYTECHNIC (CN) 2008-08-06 EP disclosed
US-20080176931-A1 e.g. 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2008-07-24 US disclosed
EP-1778663-A1 (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME The Hong Kong Polytechnic University (CN) 2007-05-02 EP disclosed
WO-2006017981-A9 (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME UNIV HONG KONG POLYTECHNIC (CN) 2006-05-11 WO disclosed
WO-2006017981-A1 (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME THE HONG KONG POLYTECHNIC UNIVERSITY (CN) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232135-A1 (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome PSMC1, PSME1, PSMB1 DYRK1A 4641/4885BACE1 1077/4885BCL2 400/4885
US-20130090300-A1 INHIBITORS OF INFLUENZA ENDONUCLEASE ACTIVITY AND TOOLS FOR THEIR DISCOVERY DNASE1, ENDOD1, RNASEH1 DYRK1A 2861/4885BACE1 277/4885BCL2 4092/4885
US-20180000774-A1 METHODS OF TREATING COGNITIVE AND BEHAVIORAL IMPAIRMENT IN DOWN SYNDROME AND ALZHEIMERS DISEASE PATIENTS CHAT, CAMK2A, CAMK1G DYRK1A 49/4885BACE1 132/4885BCL2 1640/4885
US-20160068503-A1 (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME PSMC1, PSME1, PSMB1 DYRK1A 4641/4885BACE1 1077/4885BCL2 400/4885
US-20080176931-A1 e.g. 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin UBE2G2, C9, BAP1 DYRK1A 4869/4885BACE1 2980/4885BCL2 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.